Cowealth Medical Holding Co., Ltd. AI Stock Analysis
Cowealth Medical Holding Co., Ltd. (4745) AI Stock Analysis
Cowealth Medical Holding Co., Ltd.
(TPEx:4745)
The score is weighed down primarily by deteriorating financial performance: four consecutive years of revenue decline, a severe gross margin squeeze and a swing into operating and net losses, with free cash flow falling to roughly zero. Technicals reinforce the caution, as the stock trades well below all key moving averages with a negative MACD, though extremely oversold RSI and stochastic readings leave room for a short-term bounce. Valuation adds no support, with a negative P/E driven by losses and no dividend. The main mitigating factor is a reasonably solid balance sheet — 41% equity funding of assets and a modest 0.35 debt-to-equity ratio — which buys management time, but until revenue and margins stabilize the risk profile remains elevated.
Cowealth Medical Holding Co., Ltd. (4745) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 698.63M
- Dividend Yield
- ―
- Average Volume (3M)
- 24.97K
- Price to Earnings (P/E)
- -3.2
- Beta (1Y)
- 0.31
- Revenue Growth
- -13.59%
- EPS Growth
- -221.93%
- Country
- TW
- Employees
- 919
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
Cowealth Medical Holding Co., Ltd. Business Overview & Revenue Model
Company Description
Cowealth Medical Holding Co., Ltd., together with its subsidiaries, engages in trading of medical equipment, reagents, and spare parts in Taiwan, China, and Hong Kong. It operates in two segments, Sells Equipment, and Sells Reagents and Others. The c...
Cowealth Medical Holding Co., Ltd. Financial Statement Overview
Summary
Cowealth Medical is in a pronounced downturn. Revenue has declined four years running, with the latest period down roughly 29%, while gross margin collapsed from 18.9% to 11.9%, driving a swing from a small 2024 profit to a NT$275 million operating loss and NT$247 million net loss (-8.3% net margin). Cash generation followed: operating cash flow fell from NT$374 million to NT$15.5 million and free cash flow to essentially zero, continuing a volatile multi-year pattern. The offsetting strength is the balance sheet, where equity funds about 41% of assets, debt-to-equity is a manageable 0.35 and the capital base has still edged higher — but return on equity of -8.6% shows the asset base is no longer earning for shareholders.
Income Statement
20Very NegativeBalance Sheet
55NeutralCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Jun 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.90B | 2.96B | 4.19B | 4.81B | 5.63B | 5.14B |
| Gross Profit | 386.14M | 353.22M | 791.52M | 996.45M | 1.10B | 1.06B |
| EBITDA | -256.46M | -225.35M | 168.15M | 359.59M | 470.59M | 429.04M |
| Net Income | -294.84M | -246.56M | 629.00K | 55.71M | 94.11M | 139.46M |
Balance Sheet | ||||||
| Total Assets | 7.19B | 7.04B | 6.96B | 6.64B | 7.21B | 5.40B |
| Cash, Cash Equivalents and Short-Term Investments | 636.46M | 1.14B | 1.23B | 927.28M | 1.43B | 842.68M |
| Total Debt | 601.44M | 1.01B | 872.70M | 647.24M | 956.20M | 913.34M |
| Total Liabilities | 2.27B | 1.99B | 1.76B | 1.61B | 2.00B | 1.88B |
| Stockholders Equity | 2.70B | 2.87B | 2.80B | 2.72B | 2.84B | 2.57B |
Cash Flow | ||||||
| Free Cash Flow | -543.21M | 836.00K | 316.52M | -191.47M | -293.96M | -155.04M |
| Operating Cash Flow | -532.04M | 15.53M | 373.97M | 45.02M | -267.59M | -118.38M |
| Investing Cash Flow | 76.13M | -174.03M | 40.60M | -173.28M | -271.00M | -13.51M |
| Financing Cash Flow | -142.12M | -122.23M | -238.92M | -316.48M | 1.07B | -198.56M |
Cowealth Medical Holding Co., Ltd. Peers Comparison
Overall Rating
- TW:474537Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4745 | 37Underperform | TWD 685.38M | -3.19 | ― | ― | -13.59% | -221.93% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4745 | Cowealth Medical Holding Co., Ltd. | 10.30 | -8.00 | -43.72% | |
| TW:4117 | General Biologicals Corp. | 7.41 | -5.04 | -40.48% | |
| TW:6817 | Winston Medical Supply Co., Ltd. | 37.50 | -60.57 | -61.76% | |
| TW:6999 | Han Biomedical, Inc. | 24.45 | -6.02 | -19.75% | |
| TW:7726 | CARILEX MEDICAL INC. | 32.15 | -3.95 | -10.94% | |
| TW:7835 | H2U Corporation | 14.55 | -25.40 | -63.58% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026